Desktop Genetics, a UK-based bioinformatics company, said this week that it will use £375,000 ($582,000) in funding to further develop and commercialize AutoClone, its flagship software product for designing, constructing, managing, and exchanging DNA constructs.

The funds come from an equity investment of £275,000 from Boundary Capital, Execute Technologies, and four angel investors. The firm also received an additional £100,000 from a technology strategy board grant.